Abbott Laboratories (NYSE:ABT) does about 5.53M shares in volume on a normal day but saw 17182899 shares change hands in Friday trading. The company now has a market cap of 197.04B USD and an enterprise value of about $211.68B. Its current market price is $110.79, marking a decrease of -0.45% compared to the previous close of $111.29. The 52 week high reached by this stock is $114.00 whilst the lowest price level in 52 weeks is $61.61. The script in recent trading has seen the stock touch a high of $114.195 and a low of $109.405.
Abbott Laboratories (ABT) has a 20-day trading average at $102.09 and the current price is -2.82% off the 52-week high compared with 79.82% distance from its 52-week low. The 50-day simple moving average of the closing price is $97.82 and its 200-day simple moving average is $89.31. If we look at the stock’s price movements over the week, volatility stands at 2.87%, which decreases to 1.95% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 76.72 to suggest the stock is overbought.
20 analysts observing the Abbott Laboratories (ABT) stock have set the 12-month price targets for the company’s shares at between $94.00 and $130.00. The consensus objective for the share price is $108.31, suggesting that the stock has a potential downside of -2.29% over the period. The median price target is -0.72% away from the current levels at $110.00.
FactSet Research has provided data showing that 20 brokerages have issued ratings for the stock. 2 analysts have rated it as a sell, while 2 advise that it is a overweight. 13 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 01, 2020 when Goldman downgraded the stock to “Sell” and issued a price target of $84. Goldman initiated its price target at $96.
The current price level is 9.06%, 13.74%, and 24.23% away from its SMA20, SMA50, and SMA200 respectively, with the ABT price moving above the 50-day SMA on August 28. Abbott Laboratories (ABT) stock is up 8.19% over the week and 9.12% over the past month. Its price is 27.55% year-to-date and 30.62% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $0.57 above consensus estimates by $0.15. The company’s next earnings report is expected on 10/14/2020, with forecasts estimating quarterly EPS at $0.89 and $3.28 for whole year. ABT’s earnings per share are forecast to grow by 1.20% this year and 21.00% over next year. Expected sales for next quarter are $9.36 billion, which analysts say will come at $32.94 billion for the current fiscal year and next year at $36.52 billion. In addition, estimates put the company’s current quarterly revenue at an average of $8.49 billion.
Its 12-month price target is $110.00. To reach the target analysts have set, the stock logically needs to shrink -2.29 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $94.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $130.00.
Outstanding shares total 1.77B with insiders holding 0.73% of the shares and institutional holders owning 77.18% of the company’s common stock. The company has a return on investment of 8.20% and return on equity of 10.10%. The price to earnings ratio (P/E ratio) amounts to 64.08 while the forward price to earnings ratio is 27.91. The beta has a value of 0.96. Price to book ratio is 6.42 and price to sales ratio is 6.27.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Abbott Laboratories (ABT) to 50,272,072 shares, mirroring a recent drop by -0.29%. Vanguard Total Stock Market Index dumped -0.15 million shares of Abbott Laboratories common stock bringing its total worth to about $5.06 billion at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard 500 Index Fund, which sold off -0.22 million shares to end up with 36,478,232 shares worth $3.67 billion. American Funds Investment Company cut their holdings by -1.35% in the company over the course of the most recent quarter. It now holds a 1.74% position in Abbott Laboratories thanks to 30.72 million shares amounting to $3.09 billion.